Novel cancer stem marker and its applicability for grading primary human gliomas

Evgeniya V. Dolgova, Sergey V. Mishinov, Anastasiya S. Proskurina, Ekaterina A. Potter, Yaroslav R. Efremov, Sergey I. Bayborodin, Tamara V. Tyrinova, Vyacheslav V. Stupak, Alexandr A. Ostatin, Elena R. Chernykh, Sergey S. Bogachev

Результат исследования: Научные публикации в периодических изданияхстатья

3 Цитирования (Scopus)

Аннотация

Poorly differentiated cell populations including tumor-initiating stem cells have been demonstrated to display a unique ability to natively internalize fragmented double-stranded DNA. Using this feature as a marker, we show that 0.1% to 6% of human glioblastoma cells from the bioptates can effectively internalize a fluorescently labeled DNA probe. Of these, using samples from 3 patients, 66% to 100% cells are also positive for CD133, a well-established surface marker of tumor-initiating glioma stem cells. Using the samples from primary malignant brain lesions (33 patients), we demonstrate that tumor grading significantly correlates (R = .71) with the percentage of DNA-internalizing cells. No such correlation is observed for relapse samples (18 patients).

Язык оригиналаанглийский
Страницы (с-по)1-8
Число страниц8
ЖурналTechnology in Cancer Research and Treatment
Том17
DOI
СостояниеОпубликовано - 1 янв 2018

Fingerprint Подробные сведения о темах исследования «Novel cancer stem marker and its applicability for grading primary human gliomas». Вместе они формируют уникальный семантический отпечаток (fingerprint).

  • Цитировать

    Dolgova, E. V., Mishinov, S. V., Proskurina, A. S., Potter, E. A., Efremov, Y. R., Bayborodin, S. I., Tyrinova, T. V., Stupak, V. V., Ostatin, A. A., Chernykh, E. R., & Bogachev, S. S. (2018). Novel cancer stem marker and its applicability for grading primary human gliomas. Technology in Cancer Research and Treatment, 17, 1-8. https://doi.org/10.1177/1533034617753812